RGFP963
RGFP963, or RGFP-963, is a histone deacetylase (HDAC) inhibitor which is used in scientific research.
≈ 2 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
RGFP963, or RGFP-963, is a histone deacetylase (HDAC) inhibitor which is used in scientific research. It is a selective class I HDAC inhibitor, including of HDAC1, HDAC2, and HDAC3 ( = 1,510 nM, 750 nM, and 96 nM, respectively). The drug also weakly inhibits HDAC10 ( = 6,640–10,000 nM), whereas it showed no inhibition of other HDACs at a concentration of up to 20,000 nM.
RGFP963 enhances the consolidation of cued fear extinction in rodents, with this thought to be mediated by inhibition of HDAC1 and/or HDAC2 and not by inhibition of HDAC3. In addition, the drug promotes synaptogenesis in vitro and enhances memory in an animal model of Alzheimer's disease in rodents. It also enhanced cognition in a model of amyotrophic lateral sclerosis (ALS) in rodents.
The pharmacokinetics of RGFP963 have been studied and it is brain-penetrant in rodents. RGFP963 was first described in the scientific literature by 2015.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1369059954 under CC BY-SA 4.0; modifications have been made.